PharmaVitae 2004: Bristol-Myers Squibb Global Analysis: Table of Contents

Table of Contents

PharmaVitae 2004: Bristol-Myers Squibb Global Analysis - Global analysis of Bristol-Myers Squibb's strategy, marketed portfolio, pipeline potential and financial position in 2004

Product Code: cshc1122

Price: $3800

Publication Date: 14-Jul-2004

Overview

Introduction

This analysis examines the current position and future outlook for BMS in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-7 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information

Reasons to Purchase

Benchmark BMS's performance against key rivals in the ethical pharmaceuticals sector
Evaluate the impact of BMS's high licensing dependence, at over 60% of sales on its business model
Understand why BMS has rationalized its therapeutic focus

CHAPTER 1 EXECUTIVE SUMMARY	4
Key findings	4
Current positioning: competitive outlook 2003	5
Future performance: growth drivers and resistors 2004-10	6
Evolution in therapeutic focus: 2003 - 10	8
Key issues facing Bristol-Myers Squibb: 2004 - 10	9
Strategic outlook	10
CHAPTER 2 COMPANY STRATEGY	17
Introduction to Bristol-Myers Squibb	18
Assessment of strategic position	18
Strengths	18
Weaknesses	20
Opportunities	21
Threats	22
Therapeutic foci	23
R&D productivity	24
Development opportunities	26
Organic growth	26
Partnerships/licensing	27
Mergers and acquisitions	28
Geographical expansion	29
Implications of financial position	30
CHAPTER 3 PORTFOLIO AND PIPELINE ANALYSIS	31
Therapy area focus in 2003	32
Business development by therapy area	34
Forecast revenue stream, 2004-10	36
Therapy area forecasts to 2010	36
Cardiovascular franchise	39
Marketed products	39
Pravachol (pravastatin)	40
Plavix (clopidogrel)	44
Avapro (irbesartan)	49
Monopril (fosinopril)	53
Coumadin (warfarin)	55
Capoten (captopril)	57
Questran (cholestyramine)	58
R&D compounds	58
E2F Decoy (edifoligide)	60
Factor Xa (razaxaban)	62
MaxiPost (flindokalner)	64
BMS 207940 (edonentan)	65
Vanlev (omapatrilat)	65
BMS-200980 (lanetoplase)	68
BMS-189921	68
Cardiovascular portfolio sales forecasts and forecast revenue growth	68
Oncology franchise	70
Marketed products	70
Taxol (paclitaxel)	71
Paraplatin (carboplatin)	73
Megace (megastrol acetate)	75
Ifex (ifosfamide)	76
Platinol (cisplatin)	77
VePesid (etoposide)	77
R&D compounds	78
Erbitux/IMC-C225 (cetuximab)	79
Ixabepilone (BMS-247550)	84
BMS-184476	85
BMS-214662 (farnesyl transferase inhibitor)	85
BMS-275291	85
BMS-182751/JM-216 (satraplatin)	86
Combretastatin	86
Oncology portfolio sales forecasts and forecast revenue growth	86
HIV franchise	87
Marketed products	87
Sustiva (efavirenz)	88
Zerit (stavudine /d4T)	93
Reyataz (atazanavir)	96
Videx (didanosine)	100
R&D compounds	101
DPC-083	102
BMS-488043	103
HIV portfolio sales forecasts and forecast revenue growth	105
Infectious disease franchise	106
Marketed products	106
Cefzil (cefprozil)	108
Tequin (gatifloxacin)	109
Maxipime (cefepime)	111
R&D compounds	112
Entecavir/BMS 200475	113
Ravuconazole/BMS-207147	114
Garenoxacin/desquinolone (BMS-284756)	115
Infectious disease portfolio sales forecasts and forecast revenue growth	117
CNS franchise	117
Marketed products	117
Abilify (aripiprazole)	118
Sinemet (levodopa + carbidopa)	122
Serzone (nefazodone)	123
BuSpar (buspirone)	123
R&D compounds	124
BMS-347070	125
CNS portfolio sales forecasts and forecast revenue growth	125
Diabetes and endocrinology franchise	126
Marketed products	126
Glucophage (metformin)/Glucophage XR /Glucovance (metformin and glyburide)	126
Metaglip (glipizide and metformin)	129
R&D compounds	130
Muraglitazar (BMS-298585)	131
Basulin	132
Inhaled insulin	132
Diabetes and endocrinology sales forecasts and forecast revenue growth	134
Other products	135
Marketed products	135
R&D compounds	136
abatacept (CTLA4-Ig)	137
LEA29Y	139
Other sales forecasts and forecast revenue growth	140
CHAPTER 4 CORPORATE DEVELOPMENT	141
Financial position, 2002 - 2003	142
Financial position, 2002 - 2003	142
Revenue growth	142
Cost structure and profitability	143
Liquidity, 1999-2003	144
2003 performance benchmarking	145
Business model clustering according to 2003 cost ratios	145
2003 growth and investment momentum	147
Key events shaping corporate activity, 2002-2003	149
Corporate alliances and deals	149
Solvay	150
Kereos	150
ChainDrugStore.net	151
Lexicon Genetics	151
Exelixis	151
Novartis	152
Fujisawa	152
Corgentech	152
Sequenom	152
CHAPTER 5 APPENDIX : SUPPORTING DATA	154
Financial data	154
Exchange rates	154
Methodology for therapy area forecasting	155
List of Tables
Table 1: Breakdown of Bristol-Myers Squibb's ethical sales by therapy area, 2002-03	32
Table 2: Forecast sales for Bristol-Myers Squibb's major therapy areas, 2004-10	37
Table 3: Bristol-Myers Squibb's marketed cardiovascular portfolio	39
Table 4: Bristol-Myers Squibb's cardiovascular R&D pipeline, 2004	59
Table 5: Forecast sales for Bristol-Myers Squibb's cardiovascular portfolio, 2004-10	69
Table 6: Bristol-Myers Squibb's marketed oncology portfolio	70
Table 7: Bristol-Myers Squibb's oncology R&D pipeline, 2004	78
Table 8: Forecast sales for Bristol-Myers Squibb's oncology portfolio, 2004-10	87
Table 9: Bristol-Myers Squibb's marketed HIV portfolio	88
Table 10: Bristol-Myers Squibb's HIV R&D pipeline, 2004	101
Table 11: Forecast sales for Bristol-Myers Squibb's HIV portfolio, 2004-10	106
Table 12: Bristol-Myers Squibb's marketed infectious disease portfolio	107
Table 13: Bristol-Myers Squibb's infectious disease R&D pipeline, 2004	112
Table 14: Forecast sales for Bristol-Myers Squibb's infectious disease portfolio, 2004-10	117
Table 15: Bristol-Myers Squibb's marketed CNS portfolio	118
Table 16: Bristol-Myers Squibb's CNS R&D pipeline, 2004	124
Table 17: Forecast sales for Bristol-Myers Squibb's CNS portfolio, 2004-10	125
Table 18: Bristol-Myers Squibb's marketed diabetes and endocrinology portfolio	126
Table 19: Bristol-Myers Squibb's diabetes & endocrinology R&D pipeline, 2004	130
Table 20: Forecast sales for Bristol-Myers Squibb's diabetes and endocrinology portfolio, 2004-10	134
Table 21: Bristol-Myers Squibb's other marketed products	136
Table 22: Bristol-Myers Squibb's other R&D products, 2004	137
Table 23: Forecast sales for Bristol-Myers Squibb's other portfolio, 2004-10	140
Table 24: Bristol-Myers Squibb's revenues by division, 2002-03	142
Table 25: Bristol-Myers Squibb's operating expenses, 2002-03	143
Table 26: Summary of Bristol-Myers Squibb's historical agreements, 2003-04	149
Table 27: Exchange rates, 2003	154
List of Figures
Figure 1: Competitive positioning of Bristol-Myers Squibb within the pharmaceutical market, 2003	5
Figure 2: Bristol-Myers Squibb's growth drivers and resistors, 2004-10	6
Figure 3: BMS's changing therapeutic focus, 2003-10	8
Figure 4: BMS's high dependence on partner companies to source its products affects the company's profitability, as it has to repay much of its sales to the originator company, as royalty payments	9
Figure 5: Assessment of Bristol-Myers Squibb's strategic position, 2004	10
Figure 6: Breakdown of Bristol-Myers Squibb's sales by region, 2002-03	29
Figure 7: Bristol-Myers Squib's ethical sales breakdown, 2003	34
Figure 8: Bristol-Myers Squibb's business development by therapy area	35
Figure 9: Forecast sales for Bristol-Myers Squibb's major therapy areas, 2004-10	38
Figure 10: Bristol-Myers Squibb's liquid assets versus total liabilities,1999-2003	144
Figure 11: R&D and S,G&A spend and COGS as a proportion of revenue, 2003	146
Figure 12: Benchmarking of financial strength, 2003	148

Contact Datamonitor on:

Datamonitor USA	Datamonitor Europe	Datamonitor Germany	Datamonitor Asia Pacific	Datamonitor Japan
245 Fifth Ave	Charles House	Kastor & Pollux	Darling Park	Wakamatsu Bldg 7F
4th Floor	108-110 Finchley Road	Platz der Einheit 1	Tower 2, Level 21	3-3-6 Nihonbashi-Honcho
New York, NY 10016	London NW3 5JJ	60327 Frankfurt	201 Sussex Street	Chuo-ku
USA	United Kingdom	Deutschland	Sydney, NSW 2000	Tokyo 103-0023
			Australia	Japan

t: +1 212 686 7400	t: +44 20 7675 7000	t: +49 69 9750 3119	t: +61 2 9006 1526	t: +81 3 6202 7681
f: +1 212 686 2626	f: +44 20 7675 7500	f: +49 69 9750 3320	f: +61 2 9006 1559	f: +81 3 4512 8117
e: usinfo@datamonitor.com	e: eurinfo@datamonitor.com	e: deinfo@datamonitor.com	e: apinfo@datamonitor.com	e: jpinfo@datamonitor.com

The facts of this report are believed to be correct at the time of publication but cannot be guaranteed. Please note that the findings, conclusions and recommendations that Datamonitor delivers will be based on information gathered in good faith from both primary and secondary sources, whose accuracy we are not always in a position to guarantee. As such Datamonitor can accept no liability whatever for actions taken based on any information that may subsequently prove to be incorrect.

This report is a licensed product and is not to be photocopied